

# Exact results. Actionable insights.

Exact Sciences' portfolio of genomic and genetic solutions informs personalized treatment decisions.



**EXACT  
SCIENCES**

# Building a more comprehensive experience in **oncology care.**



Transforming cancer care by providing valuable insights across the stages of diagnosis and treatment



Making it easy for providers to order tests, interpret results, and personalize medicine



Enabling patients to take a more active role in their care

## Helping you optimize crucial treatment decisions:

- Fast and actionable insights delivered on simple reports
- Covered by Medicare and many commercial insurance plans
- Financial assistance through the Genomic Access Program (GAP)
- Easy ordering through one convenient physician portal



# Our Precision Oncology portfolio.

## Treatment determination

A series of tests that offer genomic intelligence specific to the individual patient's tumor biology—equipping physicians with the insights they need.

### oncotype dx<sup>®</sup>

#### Breast Recurrence Score

The only test proven to predict likelihood of chemotherapy benefit in early stage, HR+, HER2- breast cancer.

### oncotype dx<sup>®</sup>

#### Breast DCIS Score

Quantifies the risk of local recurrence in ductal carcinoma in situ.

### oncotype dx<sup>®</sup>

#### Colon Recurrence Score

Provides a precise estimate of the risk of recurrence in stage II, T3 or T4, MMR-P, and stage III A/B colon cancers.

## Therapy selection

Leverages the underlying biology of cancer—delivering curated therapy options for each individual patient in easy-to-interpret reports.

### oncoExTra<sup>™</sup>

Ultra-comprehensive whole-exome, whole-transcriptome sequencing that generates actionable genomic insights for advanced, rare, or aggressive cancers.

## Genetic risk

Delivers deep insights to help guide treatment planning in diagnosed patients and reveal hereditary risk in undiagnosed patients.


### riskguard<sup>™</sup>

#### Hereditary Cancer Test

Multi-cancer panel that pinpoints specific high-risk genetic variants in patients and their immediate family.

# Changing lives, together.

Exact Sciences is changing the way we think about detecting and treating cancer. As a leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.



## EXACT SCIENCES

Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Colon Recurrence Score, Breast Recurrence Score, DCIS Score, Colon Recurrence Score, and OncoExTra are trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences, Cologuard and Riskguard are trademarks of Exact Sciences Corporation.

©2023 Genomic Health, Inc. All rights reserved. M-US-ES-00723

### WANT TO LEARN MORE?

[ExactSciencesPO.com](https://ExactSciencesPO.com)  
[ExactSciences.com](https://ExactSciences.com)

### WANT TO ORDER A TEST?

[provider.exactsciences.com](https://provider.exactsciences.com)  
[riskguard@exactsciences.com](mailto:riskguard@exactsciences.com)

### HAVE A QUESTION?

Oncotype: 866-662-6897  
OncoExTra: 844-539-3309  
Riskguard: 855-669-4579